Clara Rodríguez Fernández, Author at Labiotech.eu - Page 56 of 63

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

labiotech header

News and Trends 30 Nov 2016

This was Labiotech Refresh! Check our recap and highlight video!

Six months have passed since the last time we opened the doors for the very first Labiotech Refresh, Europe’s most refreshing Biotech Conference. Last week we launched our second edition live from Le Machine du Moulin Rouge in Paris! Were you not able to attend? Don’t worry! Here is our highlight video: And here’s also a […]

November 30, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

shutterstock 489589069

News and Trends 29 Nov 2016

Treating the Inner Ear: a solution for Vertigo is on the way!

Sensorion is about to start Phase II trials to treat acute severe vertigo. What makes the inner ear such an attractive target for biotech? Sensorion is a French biotech developing treatments for inner ear pathologies, including vertigo, tinnitus and hearing loss. The company has just announced the start of Phase II trials with SENS-111, a drug candidate […]

November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 501671302

News and Trends 29 Nov 2016

One Step Closer to the First Triple Combination Therapy for Cystic Fibrosis

Galapagos and AbbVie are closer to launching a cystic fibrosis treatment that can outperform the current standards. However, gene therapy and CRISPR might end up taking over in the long term. Despite being abandoned by AbbVie in its rheumatoid arthritis program, Galapagos and the big US pharma expanded their cystic fibrosis partnership in May. The […]

November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 281613872 1

News and Trends 29 Nov 2016

New British Partnership set to Cure Rare Diseases with Gene Therapy

Oxford BioMedica and Orchard Therapeutics are partnering up to bring gene therapy to the market and treat rare diseases for which no cure is available yet. Oxford BioMedica develops lentiviral vectors for gene and cell therapy applications. The company just announced a partnership with another biotech from the UK’s golden triangle, Orchard Therapeutics. The deal is […]

November 29, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 515220763

News and Trends 28 Nov 2016

Finally a Cure for the Common Cold? And it’s Needle-free!

Mucosis is starting Phase I trials for SynGEM, a needle-free vaccine against RSV, which causes 200k deaths per year and has a huge cost for both healthcare and the economy. Mucosis is a biotech from the Netherlands developing needle-free vaccines. The company has now initiated the first human trial for SynGEM, a nasal spray vaccine against […]

November 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

GlucoWise Cover 3

Interview 28 Nov 2016

Needle-Free Diabetes Monitoring: Interview with the Co-Founder of GlucoWise

The needle-free revolution for diabetes is coming! We interviewed Panos Kosmas, co-founder of MediWise, to get the juicy details of GlucoWise. This revolutionary wireless device could free the more than 422 million people living with diabetes worldwide from the daily pain of conventional glucose monitoring. Panos Kosmas is the co-founder and Chief Technical Officer of MediWise, a […]

November 28, 2016 - 4 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT

shutterstock 512105092

News and Trends 26 Nov 2016

Fruit Flies are the Artists behind these Astounding Exhibitions

The Fly Printer by Laura Beloff transforms fruit flies into artists behind pieces that highlight the limits of always making humans the point of reference in technology. Fruit flies are a very common model organism for experimentation in biotech. Now, a piece of art at the Open Fields exhibition in Riga is inverting the roles […]

November 26, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 11 22 at 1.33.19 PM e1479818165882

News and Trends 25 Nov 2016

Structural Biology meets Drug Discovery in this Cool Company

After an amazing day in Paris for Labiotech Refresh, we head back to Germany to meet Proteros. The company is working non-stop to provide drug candidates against some of the hottest targets in biotech. City: Munich, Germany Founded: 1999 Employees: 80+ Financial data: The company just announced a €157M ($167M) deal with MSD Mission: Proteros’ expertise in structural biology […]

November 25, 2016 - 1 minutemin - By Clara Rodríguez Fernández

shutterstock 519832183

News and Trends 22 Nov 2016

Fighting for the next Asthma Blockbuster: Italy gets in the way of Novartis

Chiesi has bought Atopix Therapeutics and stepped into the fight for the next asthma blockbuster. Can it take on Novartis in the competition for what is expected to grow to a €24B market in 2024? Chiesi is an Italian pharma with a strong focus on respiratory diseases. To strengthen its pipeline, the company has acquired the […]

November 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 402097858

News and Trends 22 Nov 2016

Sanofi quietly leaves Bladder Cancer Patients in the lurch

Sanofi is halting the production of the main bladder cancer drug. In response, doctors are pressuring regulatory agencies to take action against this instance of a widespread issue of drug shortages. Sanofi Pasteur announced last week that it will be shutting down the production of the cancer drug BCG (TheraCys and ImmuCyst) in mid-2017. This drug […]

November 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 451014271

News and Trends 21 Nov 2016

One Antibody to Neutralize 98% of All HIV Strains: Closer to a Cure?

A new hope for HIV: a single antibody that can target nearly all viral strains at once. What does it mean for the search of a global cure? Last week, a research article in Cell Immunity reported a detailed study of an antibody that could neutralize 98% of HIV strains. The N6 antibody can also […]

November 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

shutterstock 439844257

News and Trends 21 Nov 2016

Celyad’s Autologous CAR-T Therapy enters Phase Ib

Celyad has received approval to start Phase Ib trials in Belgium with its autologous CAR-T therapy, which can target 80% of tumors. After a successful Phase I in leukemia and myeloma, Celyad is ready to start a Phase Ib trial for its autologous NKR-2 in 7 cancer indications, now including solid tumors. The new trial, aimed to examine different […]

November 21, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

ADVERTISEMENT